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Background: The hypothesis that long term supplemental preloads of whey protein concentrate (WPC)
and soy protein isolate (SPI) 30 min before the largest meal, will improve blood pressure (BP), fasting
blood sugar (FBS) and lipid profile of overweight and obese men in their in free living condition was
tested.
Methods: Forty - five men of 52, BMI ¼ 25e40 kg/m2, after random allocation in WPC (n ¼ 26) or SPI
(n ¼ 19) groups, drank 65 gr WPC or 60 gr SPI dissolved in 500 ml water 30 min before their ad libitum
lunch for 12 weeks. Lipid profile and FBS were assessed before and after the study. Systolic and diastolic
BP were measured before and after the study and every two weeks.
Results: After 12 weeks, mean changes between the groups were significant for SBP (p < 0.02), DBP
(p ¼ 0.001), apo A-I, apo B (p < 0.001), LDL (p ¼ 0.015), HDL (p ¼ 0.017). Within group mean changes of
WPC were significant for reduction of DBP, FBS, apo B, VLDL, LDL, TG (p < 0.001), SBP, TC (p ¼ 0.001), and
for increase of apo A-I (p < 0.001) and HDL (p ¼ 0.001) relative to baseline. In SPI group, mean changes
were significant relative to baseline for decrease of SBP (p < 0.02), DBP (p ¼ 0.001), apo B (p < 0.001), LDL
(p ¼ 0.015) and for increase of apo A-I (p < 0.001) and HDL (p ¼ 0.017).
Conclusion: According to this study, WPC preloads at 30 min before ad libitum main meal, exert stronger
beneficial effects than SPI preloads on BP, FBS and lipid profile of free living overweight and obese men
after 12 weeks.
Trial registration: Iranian Registry of Clinical Trials: IRCT201109062365N3.
© 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A leading cause of cardiovascular diseases is the accelerating
increase in the prevalence of obesity with its related complications
of hypertension, dyslipidemia, diabetes and atherosclerotic
vascular disease [1]. Two major goals of dietary recommendations
are to lower blood pressure (BP) and improve serum lipids, 2 of theSchool of Public Health, Iran
9614535, Tehran, Iran.
vorgar), rezavafa@yahoo.com
ari@tums.ac.ir (M. Gohari),
n open access article under the CCprimary determinants of CVD risk [2]. In this regard, life style
modifications such as losing weight, increasing physical activity,
reducing the consumption of salt and saturated and trans fatty
acids and increasing the consumption of fruits and vegetables have
been consistently shown to improve BP, blood lipids and blood
glucose [3,4]. On the other hand, limited studies have shown
beneficial effects of high protein diets on BP, blood lipids [5e7] and
glucose [8]. Studies show that the quality and quantity of dietary
protein affect the plasma cholesterol levels [9]. Interestingly, the
inverse association between dairy consumption and metabolic
disorders [10] may be contributed to dairy-derived special com-
ponents like calcium and other minerals, whey or casein proteins
[11]. Current evidence demonstrates that ACE inhibiting peptides ofBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ACE angiotensin converting enzyme
BCAA branched-chain amino acids
WPC whey protein concentrate
SPI soy protein isolate
FBS fasting blood sugar
TC total cholesterol,
TG trilglyceride
LDL low density lipoprotein
HDL low density lipoprotein
VLDL very low density lipoprotein
Apo A-I apoliprotein A-I
Apo B apoliprotein B
BMI body mass index
IPAQ international physical activity questionnaire
SBP systolic blood pressure
DBP diastolic blood pressure
NASH nonalcoholic steatohepatitis
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in decreasing hypertension [12]. On the other hand, beneficial ef-
fects of whey protein on lipid profile are contributed to inhibiting
the expression of genes involved in fatty acid and cholesterol ab-
sorption and synthesis [13]. Furthermore, high concentrations of
BCAAs (leucine, isoleucine and valine) in whey protein have
beneficial effects on blood glucose [14]. Moreover, considering the
fact that soy protein is rich in genistein, daidzein and glycitein
isoflavones [15], it can reduce hypertension [16] and blood glucose
[17]. Additionally, twomain protein components, b-conglycinin and
glycinin also have cholesterol lowering effects [18]. Despite
numerous studies comparing effects of high protein diets from
mixed sources, studies on the effects of long term supplemental
WPC and SPI preloads before ad libitum food intake on metabolic
risk factors in overweight and obese individuals without changing
physical activity and dietary intake are scarce and similar studies
have revealed controversial results [19e23]. According to similar
interventions, whey protein either in concentrated or isolated form
is mostly compared with carbohydrate as a control group [24,25]
which masks the effects of high protein diets on metabolic factors
as a confounding factor, thus it is not obvious whether the results
are related to the high protein diet or to the specific characteristics
of the protein type for instancewhey or soy protein. Indeed, studies
evaluating effects of soy protein intake andwhey protein on apo A-I
need more investigations and also understanding which protein
sources are associated with lower CVD risk factors is important
because substituting one protein for another may help individuals
benefit from high protein diets.
Thus, the objective of the present study was to test the hy-
pothesis that preloading free living overweight and obesemenwith
supplemental WPC and SPI at 30 min before their ad libitum lunch
meals (the largest meal of obese men) can decrease BP, FBS, TC, TG,
LDL, HDL, VLDL, apo A-I and B.
2. Methods and materials
2.1. Study population and design
Volunteer employees of power plant generation of Karaj city
were recruited to participate in the study by monthly bulletin. The
study population was calculated 46 according to apo B which was
increased to 52 to prevent 12% possible participant dropouts. Atotal of 7 visits were included: one prior to the study for screening
and baseline data collection and also 1 visit at the end of weeks 2,
4, 6, 8, 10 and 12 for completing questionnaires of 24-h dietary
recalls, anthropometry and body composition measurements.
Senior researcher completed all questionnaires to minimize mis-
reporting. Of 85 volunteers, 52 men, age 30e65 yr,
BMI ¼ 25e40 kg/m2 were recruited according to the following
inclusion criteria: no cigarette smoking and alcohol consumption,
no taking medication and supplements, no high amounts of
caffeine consumption (>250e300 mg/d), no history of diseases or
clinical problems increasing oxidative stress (injuries or burns),
no allergy to soy/cow's milk and no severe weight changes within
3 last months (according to medical history of employees' records
and their physical examination by the physician of the power
plant). Exclusion criteria: changes in physical activities (PA), diets
and also a compliance of 70% or lower for consumption of treat-
ment beverages. Percent of consumed to distributed sachets were
used to assess the compliance. At visit 1, eligible participants were
randomly assigned to groups WPC or SPI (26 in each) using a
convenience allocation. Individuals were instructed to deliver
empty sachets in exchange for full ones at visits 2 to 12 for
calculating compliance. All participants had ad libitum access to
calorie and were asked to maintain their usual dietary intake and
physical activity levels during the study. They were instructed to
dissolve one sachet in 500 ml water and drink it 30 min before
lunch meal (as the largest Iranian meal) every day. Aside from
assessing compliance at biweekly visits, participants were
observed directly at random visits at lunchtime in their work-
places to ensure the supplements were taken appropriately. They
gave their written informed consent before participating in
the study. The present study was conducted according to
consolidated standards of reporting trials (CONSORT) guidelines
[26] and has been registered in the Iranian Registry Clinical Trials
(IRCT201109062365N3).
The Ethics Committee of Tehran University of Medical Sciences
approved this study (Ethics Committee: 2011-06-17-13475-43649).
2.2. Treatment beverages
Preload proteins were WPC 80% (DMV, Netherlands) and SPI
90% (Red Crown, China) with almost similar color and texture. Sa-
chets contained 67.5 g WPC and 60 g SPI (54 g effective compound
as a protein/sachet). Calorie content of WPC and SPI sachets were
261.8 Kcal and 216 Kcal respectively. They were all closely matched
for taste by strawberry flavor and sucralose (Vita Sweet, China) (0.2
gr and 0.1 gr in each sachet respectively), as a no-energy sweetener
because sucralose is not metabolized in the body and has no effect
on blood glucose or insulin secretion [27]. After packing in 4368
similar sachets for 84 days, they were numbered 1e84. The
numbers were randomly divided into groups A and B (SPI andWPC
respectively) and kept by research executive director until study
complement. Hence, all groups were blinded for both participants
and senior researcher. Protein concentration of treatment bever-
ages was 13% for WPC and 12% for SPI.
2.3. Dietary intake and physical activity assessment
All 24-h dietary recalls were completed (1 weekday and 1
weekend day) before the study and at every 2 weeks (2, 4, 6, 8 and
12) [28]. Calorie and nutrient compositions were calculated using
Nutritionist 4 software. PA was recorded by international physical
activity questionnaire (IPAQ) and recorded as metabolic equivalent/
wk (MET-Minute/Wk) [29] before the study, at the end of months 1,
2 and 3. MET values of 3.3, 4 and 8 were respectively considered for
walking, moderate and vigorous intensity activities.
Table 1
General characteristic of the participants in WPC and SPI groups.c.
WPCa SPIb P-value*
Number 26 19 0.8
Age (x±SD) 39.4 ± 6.9 38.8 ± 8.8 0.8
Height (cm) 171.1 ± 7.4 171.8 ± 8.5 0.77
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Blood pressure was measured twice every 2e3 min using a
standard mercury sphygmomanometer and the average was
recorded. This measurement was repeated every twoweeks, before
and at the end of the intervention.Body weight (Kg) 93.9 ± 11.5 95.2 ± 12.9 0.72
BMI (Kg/m2) 32.1 ± 3.2 32.1 ± 2.7 0.9
*P-values refer to comparisons between groups (independent t-test).
a Whey protein concentrate (WPC) (n ¼ 26).
b Soy protein isolate (SPI) (n ¼ 19).
c Values are mean ± SD.2.5. Measurement of fasting blood sugar and lipid profile
Fasting blood glucose and lipids weremeasured before and after
the intervention. A 10 ml fasting blood sample was taken via ven-
epuncture from participants after a 12e14 h fasting state, at base-
line and 12 weeks, to measure circulating FBS, TC, TG, HDL, LDL, apo
AI, apo B. Samples were centrifuged within 30 min of collection for
10 min at 3500 RPM. Tests of TG, TC, LDL, HDL were analyzed by
Hitach 717 and apo AI and B by Cobas Integra 400. Methods used for
measuring variables were as follows: plasma glucose levels: enzy-
matic colorimeter method based on Glucose oxidase (Eli tech di-
agnostics kit, Indonesia,0.85 103 mg/dL), apo A and B: enzymatic
immunotorbidometery method (Tina e quant Apo lipoprotein kit,
Germany), TC: enzymatic colorimeter (Eli tech diagnostics kit,
Indonesia, 1.53  103 mg/dL), LDL: enzymatic Selective Protection
(LDL-C L-Type kit, Germany,1 mg/dL), HDL: Stable Liquid Reagen
Immunoinhibition (HDL e C L-Type, Germany,0.1 mg/dL), TG:
enzymatic colorimeter (Eli tech diagnostics kit, Indonesia,
1  103 mg/dL) and VLDL: Fredlwald formula [30].2.6. Statistical analyses
All participants who completed the study were included in the
data analysis. The data are normally distributed and statistical
analysis was conducted using SPSS 17 for Windows (SPSS, Inc.,
Chicago, IL, USA). Data are assessed for normality by the Kolmo-
goroveSmirnov test. A paired t test was conducted to assess the
effects of 12week interventionwithWPC or SPI preloads on BP, FBS,
TC, TG, LDL, HDL, VLDL, apo AI and apo B. The within mean changes
of parameters were assessed by calculating differences between the
pre- and post intervention measurements. An independent t test
was conducted to compare the mean changes in parameters be-
tween the groups after 12week supplementationwithWPC and SPI
preloads. Power analysis was carried out to assess the sample size
for non significant values. Statistical power lower than 0.8 indicates
the nonsignificancy of values was due to low sample size. Values
are presented as means ± SD and statistical significance was
considered at P < 0.05.3. Results
3.1. Study population and compliance
Of 52 qualified individuals commenced the study, 7 in SPI
group quitted the study within the first 2 weeks due to gastro-
intestinal discomfort. The results were reported on the 45 in-
dividuals who completed the study (WPC: 26 men; SPI: 19 men).
Baseline characteristics of participants were not significantly
different between the groups (Table 1). PA remained unchanged
between groups when compared to baseline (Data are not
shown).
Supplements were well tolerated with 94.9% and 93.9% com-
pliances in terms of WPC and SPI consumption respectively.
After the intervention, data of 180 questionnaires of 24 h recall
and PA, 315 questionnaires of BP and 90 questionnaires of FBS, TC,
TG, LDL, HDL, VLDL, apo AI and apo B were analyzed.3.2. Dietary intake
Nutrient intakes were not significantly different between the
groups prior to the intervention (Table 2). Calorie, protein and
carbohydrate intake decreased significantly in both groups
(respectively p ¼ 0.045, p ¼ 0.21, p ¼ 0.06) as a consequence of
appetite and CI reduction (Data are not shown). Prior to the study,
dietary protein intake of participants inWPC groupwas 14.51% of CI
which increased to 16.12% of CI because of CI reduction. With
respect to the protein of WPC (17.37% of CI), total protein intake
increased to 33.5% of CI at the study completement. As well, in SPI
group, dietary protein intake was 15.46% at the beginning and
decreased to 15.03% of CI at the end of the study. Regarding the
protein of SPI (13.65% of CI), total protein intake increased to 28.7%
of CI. At week 12, WPC and SPI preloads lowered CI significantly
(p < 0.001 and p < 0.028 respectively).
3.3. Blood pressure
After intervention, individuals receiving WPC and SPI revealed
significant mean changes of SBP and DBP values between the
groups (p < 0.02 and p ¼ 0.001 respectively) (Table 3). After 12
weeks, within group mean changes of SBP and DBP
(16.6 mmHg, 7 mmHg respectively) in WPC group and within
mean changes of SBP (1.5 mmHg) and of DBP (1.9 mmHg) in the
SPI groupwere nonsignificant and significant respectively (Table 3).
3.4. Fasting blood sugar
After 12 weeks, mean changes of FBS was not significant be-
tween the groups (p ¼ 0.44) (Table 3). Within group mean changes
of FBS in WPC group (9.2 mg/dL) and in SPI group (5 mg/dL)
were significant (p < 0.001) and nonsignificant (p ¼ 0.39) respec-
tively when compared to baseline (Table 3). In both groups, there
was impaired fasting glucose at baseline which was improved at
the end of the intervention. Although not statically significant be-
tween the groups, mean changes of FBS were clinically significant
at week 12. The test power value observed was equal to 0.118 which
was lower than the regarded value and the nonsignificant differ-
ence between the groups for FBS might be due to the low test
power.
3.5. Lipid profile
Data of lipid profile evaluation results of participants are pre-
sented in Table 3. After 12 weeks, the mean changes of apo AI and
apo B were significant between the groups (p < 0.001). The within
group mean changes from baseline in apo AI of WPC group
(17.1 mg/dL) was significant (p < 0.001) but in SPI group this change
(0.9 mg/dL) was not significant (p ¼ 0.81). After 12 weeks, the
within group mean changes from baseline in apo B of WPC group
Table 2
Mean and SD of nutrient intakes of participants before and after the studyc.
Groups Before (X ± SD) After (X ± SD) *P-value yP-value
Calorie (Kcal) WPCa 2462.5 ± 621.9 1243.06 ± 303.95 0.001
SPIb 2235.1 ± 912 1582.95 ± 613.58 0.028 0.045
Protein(gr) WPC 89.35 ± 27.57 50.13 ± 21.76 <0.001
SPI 86.39 ± 19.73 59.56 ± 16.53 <0.001 0.21
Carbohydrate (gr) WPC 372.78 ± 87.57 187.15 ± 54.38 <0.001
SPI 353.83 ± 115.75 243 ± 80.17 0.009 0.006
Fat (gr) WPC 89.35 ± 27.57 50.13 ± 21.76 <0.001
SPI 70.5 ± 30.02 52.4 ± 20.88 0.045 0.09
Cholesterol (mg) WPC 251.99 ± 152.23 195.56 ± 418.47 0.4 0.37
SPI 222.13 ± 125.5 255.77 ± 148.47 0.4
Saturated fatty acid (gr) WPC 20.84 ± 152.23 10.04 ± 3.37 <0.001
SPI 20.44 ± 7.5 14.6 ± 7.1 0.02 0.09
Poly unsaturated fatty acid(gr) WPC 21.83 ± 16.87 10.76 ± 6.1 0.002 0.23
SPI 18.5 ± 10.18 12.9 ± 7.8 0.088
Mono unsaturated fatty acid(gr) WPC 23.11 ± 11.74 11.22 ± 4.5 <0.001 0.19
SPI 19.79 ± 7.6 77.11 ± 148.76 0.36
Vitamine A (RE) WPC 583.35 ± 238.3 480.94 ± 229.4 0.35 0.67
SPI 813.06 ± 840.67 836.42 ± 388.3 0.13
Vitamine C (mg) WPC 164.05 ± 128.22 63.42 ± 19.9 <0.001 0.24
SPI 145.4 ± 128.03 93.4 ± 73.68 0.14
Vitamine E (mg) WPC 20.19 ± 23 9.9 ± 5.12 0.025 0.33
SPI 16.94 ± 9.83 12.22 ± 8.25 0.15
Calcium (mg) WPC 960.19 ± 342.61 507.15 ± 168.53 <0.001 0.7
SPI 1025.6 ± 325.94 617.485 ± 203.31 <0.001
Fiber (gr) WPC 12.3 ± 8.9 9.2 ± 4.8 0.1 0.7
SPI 12.24 ± 8.9 10.34 ± 3.96 0.39
*P-values refer to comparisons between week 0 and week 12 within groups (Paired t-test).
yP-values refer to comparisons between groups (independent t-test).
a Whey protein concentrate (WPC) (n ¼ 26).
b Soy protein isolate (SPI) (n ¼ 19).
c Values are mean ± SD.
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significant (p ¼ 0.81). Before the study, apo AI was significantly
different between the groups which evaluated by ANCOVA showed
that the results were not affected by this difference and therefore
WPC supplementation on apo AI was more effective.
As it is shown in Table 3, at week 12, themean changes of TCwas
not significant between the groups (p ¼ 0.22). Within group mean
changes of TC in WPC group (16.8 mg/dL) were significant
(p¼ 0.001) but these mean changes in SPI group (7.6 mg/dL) were
nonsignificant (p ¼ 0.22) when compared to baseline. In both
groups, TC was higher than the borderline at baseline which
decreased in WPC. Although statistically nonsignificant, this
decrease was clinically significant inWPC compared to SPI. The test
power value observed was equal to 0.227 which was lower than
regarded value and the nonsignificant difference between the
groups for TC might be due to low test power.
At week 12, nonsignificant mean changes of VLDL and TG
(p ¼ 0.19) and significant mean changes of LDL, HDL (p < 0.015 and
p < 0.017 respectively) were observed between the groups. Within
group mean changes from baseline in VLDL and TG of WPC group
(8.2 mg/dL and 41.2 mg/dL respectively) were significant
(p < 0.001) but in SPI group within mean changes (3.6 mg/dL
and 18.6 mg/dL respectively) were not significant (p ¼ 0.27). The
test power value observed for VLDL and TG was equal to 0.255
which was lower than regarded value and the nonsignificant dif-
ference between the groups for VLDL and TG might be due to low
test power. Before the study TG in WPC group was high and in SPI
was in high borderline which decreased after 12 weeks. Although
this decrease was nonsignificant statistically between the groups,
the within group mean changes in WPC group were clinically sig-
nificant compared to SPI group.
After 12 weeks, the mean changes from baseline in LDL and HDL
of WPC group (13.5 mg/dL and 4.3 mg/dL respectively) were
significant (p < 0.001 and p ¼ 0.001 respectively) but in SPI groupmean changes (0.9 mg/dL and 0.38 mg/dL respectively) were not
significant (p ¼ 0.86 and p ¼ 0.73 respectively). Before the study,
HDL was significantly different between the groups which evalu-
ating with ANCOVA showed that the results were not affected by
this difference and therefore WPC supplementation on HDL was
more effective.
4. Discussion
The results of this 12-week randomized, double blind clinical
trial in free living overweight and obese men indicate that WPC
exerted stronger effects on decreasing SBP, DBP, FBS and on
improving lipid profile of participants than SPI did. Accordingly, we
confirmed the research hypothesis that supplemental preloads of
WPC and SPI at 30 min before the largest meal of overweight and
obese men would decrease SBP, DBP, FBS and improve lipid profile
of participants although WPC was stronger than SPI.
BP in the present study changed in consistent with a previous
study in overweight and obese individuals [25]. In contrast, in a
study in NASH patients, whey consumption led to nonsignificant
increase of SBP and DBP [20] which is likely due to low dose of
supplement and high degree of oxidative stress in the patients
unlike our health participants. In other clinical trials, BP revealed no
change after receiving 35 gr soy nuts by women with metabolic
syndrome [23] or after 30 gr ingesting soy protein containing
132 mg phytoesterogen by postmenopausal women with type 2
diabetes [31]. These disagreements may result from low dose of soy
protein and low BP of participants. Overall, in the present study the
amount of isoflavones were not enough to influence the BP and BP
reduction observed here seem to be a result of the protein intake
itself [32].
Mean FBS decreased in WPC significantly and in SPI nonsignif-
icantly. Interestingly, this finding was similar to a previous study
[33] but unlike our participants with ad libitum food intake, in that
Table 3
Effects of 2-wk supplementation with WPC and SPI preloads on metabolic indices before and after the studym.
Groups Before (X ± SD) After (X ± SD) Mean changes *P-value
SBPc (mmHg) WPa 131.3 ± 11.6 114.7 ± 22.4 16.6 ± 10.8 0.001
SPIb 118.8 ± 29.3 120.3±11.4 1.5 ± 17.9 0.81
p-valuey <0.02
DBPd (mmHg) WPC 83.1±16 76.1±14.2 7 ± 1.8 <0.001
SPI 80.8 ± 8 78.9 ± 6.6 1.9 ± 1.4 0.031
p-valuey 0.001
FBSe (mg/dl) WPC 103.1 ± 10.8 94.1 ± 9.5 9 ± 1.3 <0.001
SPI 107.4 ± 48.1 102.4 ± 42.4 5 ± 5.7 0.39
p-valuey 0.44
Apo A-If (mg/dl) WPC 135.3 ± 12.1 152.4 ± 12.1 17.1 <0.001
SPI 144.9 ± 19.2 145 ± 3.7 0.9 ± 15.5 0.81
p-valuey <0.001
Apo Bg WPC 135.3 ± 12.1 152.4 ± 12.1 17.1 <0.001
SPI 144.9 ± 19.2 145.8 ± 3.7 0.9 ± 15.5 0.81
p-valuey <0.001
TCh(mg/dl) WPC 200.5 ± 32.2 183.7 ± 30.9 16.8 ± 1.3 0.001
SPI 210.2 ± 36.8 202.6 ± 38.8 7.6 ± 2 0.22
p-valuey 0.22
VLDLi (mg/dl) WPC 40.9 ± 12.2 32.7 ± 11.1 8.2 ± 1.1 <0.001
SPI 38.9 ± 18.4 35.3 ± 13.5 3.6 ± 4.9 0.27
p-valuey 0.19
LDLj (mg/dl) WPC 123.4 ± 24.7 109.9 ± 22.8 13.5 ± 1.9 <0.001
SPI 127.6 ± 29.2 128.5 ± 32.9 0.9 ± 3.7 0.86
p-valuey 0.015
HDLk (mg/dl) WPC 38.2 ± 3.9 42.5 ± 7.6 4.3 ± 3.7 0.001
SPI 41.82 ± 6.6 42.2 ± 6.8 0.38 ± 0.6 0.73
p-valuey 0.017
TGl (mg/dl) WPC 204.8 ± 60.9 163.6 ± 55.5 41.2 ± 5.4 <0.001
SPI 194.9 ± 91.9 176.3 ± 67.4 18.6 ± 24.5 0.27
p-valuey 0.19
Groups Before (±SD) After (±SD) Mean changes *P-value.
*P-values refer to comparisons between week 0 and week 12 within groups (Paired t-test).
yP-values refer to comparisons between groups (independent t-test).
a Whey protein concentrate (WPC) (n ¼ 26).
b Soy protein isolate (SPI) (n ¼ 19).
c Systolic blood pressure (SBP).
d Diastolic blood pressure (DBP).
e Fasting blood sugar (FBS).
f Apolipoprotein AI (Apo AI).
g Apolipoprotein B (Apo B).
h Total cholesterol (TC).
i Very low density lipoprotein (VLDL).
j Low density lipoprotein (LDL).
k High density lipoprotein (HDL).
l Triglyceride (TG).
m Values are mean ± SD.
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weight gain which might influence the results. In addition,
comparing whey with glucose is definitely effective on the signif-
icant results. The main reason of blood glucose decrease by whey
protein, is its low glycemic index and carbohydrate content, amino
acids stimulating insulin or incretin hormone secretion and gastric
emptying [34]. In another study FBS did not change significantly
[35], which was likely due to the short duration of the study (4
weeks compared with this 12 week intervention). From 1910 that
the beneficial effects of soy protein on diabetes proposed for the
first time [36], limited studies on diabetic patients show that this
effect is due to soluble fiber contents in soy bean [37]. According to
a previous study soy protein ingestion led to significant reduction
in insulin resistance and HbA1c and to a significant increase in FBS
[31], in which similar to ours, soy protein lacked soluble fiber but
the amount of isoflavone intake was higher than our study.
Furthermore, studies demonstrate that many metabolic effects of
soy protein are specific to women but whether a sex effect is
evident for glycemic control is unclear [31]. A reason for no sig-
nificant difference in FBS of SPI group might be due to higher in-
sulin resistance in themorning resulting from fasting period duringthe night [38] whilst BCAAs of whey can stimulate insulin more
than soy. As well, WPC decreased carbohydrate intake more than
SPI. Additionally, high levels of cystein in whey protein increases
taurin synthesis in liver [39] which can increase mRNA of apo A-I
[40]. After the intervention, the increase in average apo A-I was
significant in WPC group and was nonsignificant in SPI group and
the mean changes between the groups were significant. To our
knowledge, no human study has investigated the effect of whey
protein on apo A-I on obese individuals but regarding the inverse
association between apo A-I, the main protein of HDL, and obesity
[41], the increase in apo A-I by whey protein can be due to much
decrease of abdominal obesity in this group (data not shown) and
also due to sulfuric amino acids of whey protein. Similarly, in a
previous randomized double blind crossover [42], lack of signifi-
cant changes in apo A-I may result from lower levels of apo A-I at
baseline in soy group when comparing with the present study. In
contrast, apo A-I increase in another study [23] may be a result of
higher intakes of fiber, isoflavone and unsaturated fatty acids by soy
protein ingestion.
At the end of the study, the mean changes of apo B in whey
group decreased significantly and increased nonsignificantly in SPI
A. Tahavorgar et al. / Journal of Nutrition & Intermediary Metabolism 2 (2015) 69e7574group and mean changes between the groups were significant but
Pipe et al. observed no significant effects on apoB despite of sig-
nificant decrease of apoB/apo A-I ratio [42] whereas in another
study, supplementation with soy protein decreased apo B100
significantly [23] that can be attributable to higher apo B100 at
baseline (150 mg/dL) compared with lower level (105.3 mg/dL)
in the current study which lead to better results after soy
supplementation.
TC decreased significantly in WPC but nonsignificantly in SPI
group. In accordance with this finding, some other studies reported
a significant reduction in TC after supplementation with whey
[25,35]. However, in a study TC did not change [21], which may be
due to lower levels of cholesterol at baseline, short term of the
intervention, low dose of protein and not consuming the supple-
ment before the meal to provide plenty time for BCAA of whey
protein to exert favorable effects. In contrast, evidence show, 30 gr
consumption of SPI [31,43] was able to lower TC significantly. High
amounts of leucin in whey protein may contribute to TC reduction
which data on molecular mechanism is limited [44]. Soy protein
through its high concentration of arginin [45] and also through
promoting excretion of cholesterol and bile acids in feces, can
decrease blood cholesterol [46].
After completing the study, VLDL in WPC group decreased
significantly and in SPI group nonsignificantly. The reason behind
the inconsistency of these results with previous one [23] may result
from some sex dependant effects of soy protein [31]. LDL in WPC
group at study completion decreased significantly and in SPI group
increased nonsignificantly. Mean changes of LDL between two
groupswere significant. Thisfindingwas in agreementwith another
research [25]. But nonsignificant reduction of LDL [20] or no change
of it [21] in some studies may be attributed to low dose of protein
intake and not consuming the supplement before meals. Unlike the
current study, soy protein used in other studies led to significant
decrease in LDL [23,31,42] which may result from low contents of
fiber, isoflavone and unsaturated fatty acids in SPI in this study.
After this intervention, the observed increase of HDL was sig-
nificant in WPC group and nonsignificant in SPI group. The mean
changes between the groups was significant. Lack of significant
changes of HDL level in other researches [25,35] may be induced by
higher HDL levels compared to low HDL levels in the present study
and in a similar one [42] and also short term supplementation and
low dose of whey intake before the meal. Similarly, in some other
studies soy intake caused a significant increase in HDL [43]. This,
can be explained by sulfuric amino acids like metionin, cystein and
taurin that are able to increase apo A-I and decrease apo B which
increase HDL and decrease LDL and VLDL respectively [47].
High concentration of plasma TG is often associated with low
HDL concentration [48]. At the end of the study, TG decreased
significantly in WPC group and nonsignificantly in SPI group. The
same results in other studies [25,36] are reported that can be
explained by decrease of glucagon to insulin ratio and by decrease
in carbohydrate and fat intake after whey consumption [36]. Con-
firming this finding, we can point to the studies in which TG
decreased by 30 gr soy protein consumption [43,49] that is
inconsistence with other studies [31,38].The mechanism of the ef-
fect of whey protein on TG metabolism is still unknown. TG
metabolism is influenced by factors including: intestinal secretion
of chylomicrons, hepatic secretion of VLDL and uptake of lipopro-
teins by tissues lacking TG [50] and probably whey protein affecting
one of these stages, lowers TG. Based on a meta-analysis by Zhan
et al. of data from 23 studies, soy protein with isoflavone reduces
TC, LDL and TG significantly and the magnitude of these effects is
not only dose dependent but also is associated with the length of
supplementation period and baseline concentration of cholesterol
[51]. Another possible reason of not improving serum lipids in soygroup can be attributed to the individual differences in intestinal
absorption of isoflavones. Isoflavone equol is not produced at the
same amount in all people in response to soy protein intake and
this is of importance in various effects of soy protein on serum
lipids [52] which seems that this effect of whey is independent of
weight and body fat decrease [53].
Major strengths of present study include: it was a randomized
double blinded design and conducting it in participants' workplace
which caused a precise monitoring the intervention. Given that
different proteins exert different effects depending on dose, source
and intake time, we determined the largest meal which was lunch,
and supplemented participants with a complete dose of 65 gr WPC
and 60 gr SPI equal to 52 gr effective material as protein, 30 min
before lunch for 12 weeks. Unlike previous studies that evaluated
the effects of substituting dietary proteins from mixed protein
sources [54e57], this study revealed beneficial effects of WPC and
SPI preloads on Bp, FBS and lipid profile of participants. Besides,
comparing two different sources of proteins in this study helpt us
rule out the effect of high protein diets on metabolic factors as a
confounding factor. Because we were interested to evaluate bio-
logical impacts of soy protein, not its non protein components, and
since isoflavone contents of isolated forms of soy are much lower,
we so used SPI. Hence, these results were due to isoflavone free
components of SPI including its proteins. On the other hand, ac-
cording to literature review, there are limited studies on the impact
of long time whey and soy protein preloads on apo A-I in free living
overweight and obese individuals. Limitations of this study that are
suggested to be taken into consideration in future studies are not
measuring plasma amino acids before and after the intervention.
In conclusion, the hypothesis was confirmed and supplemental
preloads of WPC and SPI have been shown to decrease BP and FBS
and to modify lipid profile of healthy overweight and obese men
in their free living conditions, although WPC exerted stronger
impacts.
5. Conclusion
This study demonstrated that long term supplemental preloads
with WPI and SPI can improve metabolic risk factors associated in
overweight and obese individuals though the effects of WPC were
higher. The first major finding was that beneficial effects of WPC
and SPI liquid preloads on metabolic risk factors in overweight and
obese individuals are independent of body weight and body
composition changes as food intake and body weight decreased in
both groups (data not presented). Another major finding is that
favorable changes of metabolic risk factors by SPI not only depend
on its isoflavones and fiber but also on beneficial amino acids of soy
protein.
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